lulizumab pegol   Click here for help

GtoPdb Ligand ID: 8460

Synonyms: BMS-931699 | BMS931699
Immunopharmacology Ligand
Compound class: Antibody
Comment: Lulizumab pegol is a humanised PEGylated anti-CD28 antibody-based biologic, developed as a potential treatment for autoimmune diseases. This so-called domain antibody (dAb) contains the smallest functional binding unit and lacks the divalent structure characteristic of a complete antibody [3]. PEGylation improves solubility and extends circulating half-life [2].
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD28 Primary target of this compound Hs Antibody Binding 9.3 – 9.4 pKd - 3
pKd 9.3 – 9.4 (Kd 5.1x10-10 – 3.6x10-10 M) [3]
Description: Note that this Kd value was determined using the 'naked' binding component, in the absence of PEGylation.